Frederique van Baarle assumes position on the LANXESS Board of Management
Frederique van Baarle has taken up her position as a member of the Board of Management and Labor Director at Cologne-based specialty chemicals company LANXESS effective April 1, 2023. Until the end of March van Baarle headed the High Performance Materials business unit at LANXESS, which was contributed to a joint venture for high-performance plastics with private equity firm Advent on April 1. The 51-year-old had already been appointed by the Supervisory Board in November 2022.

Frederique van Baarle, member of the Board of Management and Labor Director at LANXESS
LANXESS
Van Baarle will also assume board responsibility for the Americas region from the second half of 2023. She will perform her new role from Pittsburgh, LANXESS’ U.S. headquarters.
Other news from the department business & finance

Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Utrafast magnetism: electron-phonon interactions examined at BESSY II

ts-systemfilter gmbh - Ahorn, Germany

Spectrum Inspections Systems Ltd - Farnborough, United Kingdom
Dow Introduces TRITON(TM) EF and TERGITOL(TM) L Low Foam Surfactants - New Product Line Combines Environmental Viability with High Performance
Messe München acquires lab-technology trade fair Lab Africa - Expansion of the analytica network
GlaxoSmithKline and Anacor Pharmaceuticals form alliance to develop systemic antivirals and antibiotics based on boron chemistry
